An alternative approach is to limit a prospective study to subjects with hyperuricemia who do not have any other cardiovascular, metabolic, or renal risk factors. Here we investigate Abstract-Whether asymptomatic hyperuricemia in the absence of comorbidities increases the risk for cardiometabolic disorders and chronic kidney disease remains controversial. This study was conducted to clarify the association between asymptomatic hyperuricemia and cardiometabolic conditions. Subjects consisting of Japanese adults between 30 and 85 years of age were enrolled in the study at Center for Preventive Medicine, St Luke's International Hospital, Tokyo, and were available at enrollment (2004) and at 5-year follow-up (2009). Subjects were excluded if they were overweight or obese, hypertensive, diabetic, and dyslipidemic, had a history of gout or hyperuricemia on medications, or had chronic kidney disease as estimated glomerular filtration rate <60 mL/min per 1.73 m 2 . Linear and logistic regression analyses were used to examine the relationship between hyperuricemia and development of hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, and overweight/obesity (unadjusted and adjusted for age, sex, smoking, drinking habits, baseline estimated glomerular filtration rate, and body mass index). Five thousand eight hundred and ninety-nine subjects without comorbidities (mean age of 47±10 years, 1864 men) were followed for 5 years. Hyperuricemia (defined as >7 mg/dL in men and ≥6 mg/dL in women) was associated with increased cumulative incidence of hypertension (14.9% versus 6.1%; P<0.001), dyslipidemia (23.1% versus 15.5%; P<0.001), chronic kidney disease (19.0% versus 10.7%; P<0.001), and overweight/obesity (8.9% versus 3.0%; P<0.001), while diabetes mellitus (1.7% versus 0.9%; P=0.087) showed a trend but did not reach statistical significance. In conclusion, asymptomatic hyperuricemia carries a significant risk for developing cardiometabolic conditions in Japanese individual without comorbidities. (Hypertension.
H yperuricemic subjects frequently have other comorbidities, such as obesity, metabolic syndrome, hypertension, and chronic kidney disease (CKD). 1 Originally most investigators thought that the reason hyperuricemia is common in these conditions is because serum uric acid (SUA) may be passively elevated because of the effects of insulin resistance, renal vasoconstriction, and reduced estimated glomerular filtration rate (eGFR) to reduce uric acid excretion by the kidneys. 1 However, experimental studies of hyperuricemia have suggested that uric acid may have an independent modulatory or causal role in these conditions. [2] [3] [4] Consistent with these findings, an elevated SUA has been consistently found to predict the development of hypertension, diabetes mellitus (DM), and CKD. [5] [6] [7] Unfortunately, because many of the subjects with hyperuricemia have comorbidities, it can be difficult to tease out the role of uric acid from coexistence of the other comorbid conditions. Although multivariable analysis can be used to control for these other conditions, multivariable analysis can be misleading if the associated risk factors are causally linked. The limitations associated with multivariable analysis as a means for determining causation are well known.
whether asymptomatic hyperuricemic subjects without comorbidities have an increased risk for cardiometabolic disorders.
Methods

Study Design and Study Subjects
This study was a large-scale, single-center, retrospective cohort study. We used the database at the Center for Preventive Medicine, St Luke's International Hospital, Tokyo, Japan. This study population was an apparently healthy population because they came to the center to have annual regular health check-up by themselves and also provided a general history for comorbidities. Some studies were published using this database. [10] [11] [12] [13] [14] We enrolled the study subjects between 30 and 85 years old whose data were available at 2004 and 2009. Of those, we excluded the subjects with hypertension, DM, dyslipidemia, CKD whose eGFR was <60 mL/min per 1.73 m 2 , overweight or obesity whose body mass index (BMI) was ≥25 kg/m 2 , and hyperuricemia or gout who had medication in 2004. We also made additional analyses without the subjects whose eGFR was <75 mL/min per 1.73 m 2 in 2004 because an eGFR of 60 to 75 mL/min per 1.73 m 2 still qualifies as abnormal renal function, despite not being defined as CKD.
We compared cumulative incidences of hypertension, DM, dyslipidemia, CKD, and overweight/obesity over 5 years between hyperuricemia and normouricemia and calculated odds ratios (ORs) for each disease by crude analysis and after adjustments for age, sex, and smoking and drinking habits (Model 1), with the addition of baseline eGFR (Model 2), and with the addition of BMI (Model 3). Furthermore, we calculated cumulative incidences of hypertension, DM, dyslipidemia, CKD, and overweight/obesity over 5 years for various levels of SUA, including ≤3.0, 3.1 to 4.0, 4.1 to 5.0, 5.1 to 6.0, 6.1 to 7.0, 7.1 to 8.0, and ≥8.1 mg/dL.
Patient Involvement
No patients were involved in setting the research question or outcome measures, nor were they involved in the design and implementation of the study. There are no plans to involve patients in dissemination.
Definition of Hyperuricemia, Hypertension, DM, Dyslipidemia, and CKD Hyperuricemia was defined as >7.0 mg/dL of SUA in men and ≥6.0 mg/dL in women as the standard definition for most studies. This definition in men was attributed to Japanese guideline for the management of hyperuricemia and gout: second edition. 15 However, compared with men, SUA levels are lower in women. 16 Thus, we defined hyperuricemia in women as ≥6.0 mg/dL as is commonly used in other study populations. [17] [18] [19] [20] Hypertension was defined as the subjects who had current antihypertensive medication or systolic blood pressure (BP) of ≥140 mm Hg or diastolic BP of ≥90 mm Hg according to the Japanese Society of Hypertension guidelines (JSH 2014). 21 BP readings were obtained using an automatic brachial sphygmomanometer (OMRON Corporation, Kyoto, Japan). Two BP examinations were taken after the participant had been seated and resting quietly for >5 minutes with feet on the ground and back supported. The mean systolic and diastolic BP of each of the participants were calculated from the recorded measurements. DM was defined as the subjects who had current history of DM or glycated hemoglobin A1c (HbA1c) (National Glycohemoglobin Standardization Program) of ≥6.5% according to International Expert Committee. 22 Dyslipidemia was defined as the subjects who had current medication for dyslipidemia or whose low-density lipoprotein cholesterol was ≥140 mg/dL, high-density lipoprotein cholesterol was <40 mg/dL, and/or triglyceride was ≥150 mg/dL according to Japan Atherosclerosis Society guidelines. 23 
Statistical Analysis
The statistically significant level was set α=0.05, and all statistical analyses were 2-sided. Data are expressed as mean±standard derivation or as percent frequency, unless otherwise specified. Comparisons between 2 groups were performed with t tests for normally distributed variables and χ 2 analyses for categorical data. The risk factors for each disease were evaluated by multivariable logistic regression models with adjustments for age, sex, BMI, smoking, drinking habit, and baseline eGFR. We analyzed the ORs of risk for each disease state. Furthermore, because the distribution of SUA differed between men and women, multivariable regression analyses were also stratified by sex. All the statistical analyses were performed by the SPSS Statistics software (IBM SPSS Statistics version 22 for Windows; IBM, New York).
Ethical Considerations
We adhere to the principles of the Declaration of Helsinki. All data were collected and compiled in a protected computer database. Individual data were anonymous without identifiable personal information. St Luke's International Hospital Ethics Committee approved the protocol for this study. Consents were obtained from all subjects by a comprehensive agreement method provided by the hospital.
Results
Demographics
There were 13 201 subjects who underwent annual medical examination at the hospital both in 2004 and in 2009. We excluded 121 subjects who were <30 years of age and 10 subjects who were >85 years old in 2004. Of the remaining 13 070 subjects, we excluded 7171 subjects with comorbidities as baseline: 2599 with hypertension, 575 with DM, 5188 with dyslipidemia, 492 with CKD, 2653 who were overweight/obesity, and 373 subjects with hyperuricemia or gout who were on medication. Finally, we analyzed 5899 study subjects ( Figure 1 ). Moreover, we made an additional analysis of 4915 subjects whose eGFR was ≥75 mL/min 1.73 m 2 in 2004 who lacked comorbidities. Of a total of 13 070 subjects, we excluded 8155 subjects, including 2599 with hypertension, 575 with DM, 5188 with dyslipidemia, 2653 who were overweight/obesity, and 373 subjects with hyperuricemia or gout who were on medication, and 3338 subjects whose eGFR was <75 mL/min per 1.73 m 2 at the 2004 baseline examination ( Figure S1 in the online-only Data Supplement).
The study subjects' demographic data whose eGFR was ≥60 mL/min per 1.73 m 2 is shown in Table 1 and those whose eGFR was ≥75 mL/min per 1.73 m 2 is shown in Table S1 . As can be observed, hyperuricemic subjects showed mild but significant differences from normouricemic subjects for systolic and diastolic BP, BMI, and estimated GFR, despite both groups having values within the normal range. We compared the cumulative incidence of hypertension, DM, dyslipidemia, CKD, and overweight/obesity over 5 years for subjects with hyperuricemia compared with those with normouricemia ( Figure 2 ). In the analysis in which subjects all had baseline eGFR of >60 mL/min per 1.73 m 2 , hyperuricemic subjects showed significantly higher cumulative incidence of hypertension (14 (Figure 2, total) .
We also compared the cumulative incidences for various cardiometabolic conditions between hyperuricemia and normouricemia by sex. In men, hyperuricemic subjects (>7.0 mg/ dL of SUA) showed significantly higher cumulative incidence of hypertension (14.2% versus 9.2%; P=0.011), dyslipidemia (25.2% versus 19.2%; P=0.020), CKD (17.4% versus 12.4%; P=0.022), and overweight/obesity (11.0% versus 4.9%; P<0.001) than normouricemic subjects, while DM (1.4% versus 1.6%; P=0.782) showed no significant difference (Figure 2 , men). In women, hyperuricemic subjects (defined as ≥6.0 mg/dL of SUA) showed significantly higher cumulative incidence of hypertension (16.5% versus 4.8%; P<0.001), DM (2.3% versus 0.5%; P=0.011), and CKD (22.6% versus 10.0%; P<0.001) compared with normouricemic subjects, while dyslipidemia (18.8% versus 14.0%; P=0.118) and overweight/obesity (4.5% versus 2.2%; P=0.080) were not significantly different (Figure 2 , women).
Similar analyses were performed comparing subjects with asymptomatic hyperuricemia to normouricemia who had baseline eGFR ≥75 mL/min per 1.73 m 2 . Hyperuricemia subjects showed significantly higher cumulative incidence of hypertension (16.5% versus 5.6%; P<0.001), dyslipidemia (26.4% versus 15.3%; P<0.001), and overweight/obesity (9.5% versus 3.0%; P<0.001) than normouricemic subjects, while DM (1.8% versus 0.8%; P=0.062) showed a trend but was not significant ( Figure S2 , total). Interestingly, the trend for developing CKD was greater in normouricemic subjects (1.8% versus 4.0%; P=0.071). In men, hyperuricemic subjects showed significantly higher cumulative incidence of hypertension (15.6% versus 8.4%; P=0.001), dyslipidemia (30.2% versus 19.4%; P<0.001), and overweight/obesity (12.5% versus 4.9%; P<0.001) than normouricemic subjects, while DM (1.0% versus 1.4%; P=0.656) and CKD (2.6% versus 3.4%; P=0.576) had no significant differences ( Figure S2 , men). In women, hyperuricemic subjects showed significantly higher cumulative incidence of hypertension (18.5% versus 4.5%; P<0.001) and DM (3.7% versus 0.5%; P<0.001) than normouricemic subjects, while dyslipidemia (17.3% versus 13.7%; P=0.362), CKD (0.0% versus 4.2%; P=0.058), and overweight/obesity (2.5% versus 2.2%; P=0.889) had no significant difference ( Figure S2 , women).
Multivariable Adjustments
In the group whose eGFR was ≥60 mL/min per 1.73 m 2 , after adjustments with age, sex, and smoking and drinking habit, hyperuricemia became an independent risk factor for hypertension (OR, 2.05; 95% confidence interval [CI], 1.51-2.79), dyslipidemia (OR, 1.41; 95% CI, 1.10-1.81), CKD (OR, 1.80; 95% CI, 1.36-2.38), and overweight/obesity (OR, 2.37; 95% CI, 1.60-3.52) but not for DM (Table 2 , total, Model 1). After adjustment included eGFR, hyperuricemia did not become an independent risk factor for CKD (Table 2 , total, Model 2). After adjustment included BMI, hyperuricemia did not become an independent risk factor for overweight/obesity ( In the group whose eGFR was ≥75 mL/min per 1.73 m 2 , after adjustments with age, sex, and smoking and drinking habit, hyperuricemia became an independent risk factor for hypertension (OR, 2.78; 95% CI, 1.93-4.01), dyslipidemia (OR, 1.73; 95% CI, 1.29-2.32), and overweight/obesity (OR, 2.38; 95% CI, 1.50-3.78), but not for CKD or DM (Table S2 , total, Model 1). After adjustment included eGFR, hyperuricemia became an independent protective factor for CKD (OR, 0.38; 95% CI, 0.15-0.96) (Table S2 , total, Model 2). Similar findings were noted after adjustment with the addition of BMI (Table S2 , total, Model 3). In men, hyperuricemia remained an independent risk factor for hypertension ( Data are presented as mean±standard deviation. ALT indicates alanine transaminase; AST, aspartate transaminase; BP, blood pressure; bpm, beats per minute; BUN, blood urea nitrogen; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; γGTP, γ-glutamyl transpeptidase; P, probability; and SUA, serum uric acid.
Cumulative Incidences of Each Disease Between 2004 and 2009 by Sex for Various Levels of Serum Uric Acid
In the group whose eGFR was ≥60 mL/min per 1.73 m 2 , we calculated cumulative incidences of hypertension, DM, dyslipidemia, CKD, and overweight/obesity over 5 years by sex for each SUA levels: ≤3.0, 3.1 to 4.0, 4.1 to 5.0, 5.1 to 6.0, 6.1 to 7.0, 7.1 to 8.0, and ≥8.1 mg/dL. The number of subjects was 10, 91, 281, 658, 542, 229, and 53 in men and 276, 1362, 1732, 550, 101, 14, and 0 in women, respectively. The results showed that higher SUA had higher cumulative incidence of hypertension, dyslipidemia, CKD, and overweight/obesity both in men and in women and DM in women (Figure 3) .
In the group whose eGFR was ≥75 mL/min per 1.73 m 2 , the number of subjects was 10, 69, 228, 515, 422, 156, and 36 in men and 258, 1257, 1479, 416, 59, 10, and 0 in women, respectively. The results showed higher SUA had higher cumulative incidence of hypertension both in men and in women, dyslipidemia and overweight/obesity in men, and DM in women ( Figure S3 ).
Discussion
The primary finding of our study was that asymptomatic hyperuricemic subjects without comorbidities had a significant increased risk for developing hypertension (2.7-fold), dyslipidemia (1.6-fold), overweight/obesity (3.2-fold), and CKD (2.0-fold) and a nonsignificant trend for developing DM (2.0-fold).
These studies document that the presence of hyperuricemia is an important biomarker for cardiovascular and renal risk, but these studies do not evaluate whether hyperuricemia has a causal role in the development of these conditions. Multivariable analysis was also performed to determine whether the increased risk of asymptomatic hyperuricemia for these specific conditions was independent of age, sex, and smoking and drinking habits (Model 1), or with the addition of baseline eGFR (Model 2), or with the addition of baseline BMI (Model 3). In the group whose eGFR was ≥75 mL/min per 1.73 m 2 , hyperuricemia became an independent risk factor for hypertension, dyslipidemia, CKD, and overweight/obesity in Model 1, but in Model 2, the risk for CKD was no longer independent after controlling for baseline eGFR. Moreover, in Model 3, the risk for overweight/obesity was also no longer independent after controlling for baseline BMI.
This shows that the risk for CKD and overweight/obesity to increase in hyperuricemic subjects is linked with the baseline eGFR and BMI in hyperuricemic subjects, respectively. Importantly, this simply shows that the variables are linked and does not speak toward causality. For example, the finding that baseline eGFR is not independent of SUA as a risk factor for CKD could reflect the possibility that even early on a mild reduction in eGFR might increase the risk for hyperuricemia by reducing the renal excretion, or conversely, it might suggest that there is a subset of subjects with hyperuricemia (such as those with hyperuricemia because of increased xanthine oxidase activity) that are developing subtle decreases in renal function. Likewise, a similar explanation could be used to explain why controlling for baseline BMI results in hyperuricemia no longer predicts the development of overweight/ obesity. For example, it might be that even subtle differences in weight drive up SUA levels, or that SUA might already be driving obesity early on, or even that another factor (eg, insulin resistance) might be driving both. In addition, the risk for CKD actually was less in subjects with hyperuricemia for subjects with eGFR >75 mL/min per 1.73 m 2 after multivariable adjustments that included correcting for baseline eGFR. One potential explanation may be that when one removes the effects of baseline eGFR, that the potential benefit CI indicates confidence interval; CKD, chronic kidney disease; GFR, glomerular filtration rate; OR, odds ratio; and SUA, baseline serum uric acid level. *Model 1: Data adjusted for age, sex, and smoking and drinking habits. †Model 2: Data adjusted for age, sex, body mass index, smoking and drinking habits, and baseline estimated GFR. ‡Model 3: Data adjusted for age, sex, body mass index, smoking and drinking habits, baseline estimated GFR, and body mass index.
of SUA as an antioxidant may manifest. An alternative possibility is that there is a subset of subjects with lower SUA who may also be at risk for CKD, such as because of a mutation or reduced function in a urate transporter that results in enhanced uricosuria. Merriman's group, for example, reported that organic anion transporter 4 polymorphisms that result in enhanced urate reabsorption into the blood and decrease urinary urate excretion are protective for CKD. 25 Again, it is important to note that the issue of whether uric acid is independent or not does not equate with causality 8 and that the primary finding is that asymptomatic hyperuricemia is a potent predictor of hypertension, overweight/obesity, and CKD.
We also conducted additional multivariable analyses to clarify the odds ratio of hypertension, DM, and dyslipidemia with the addition of baseline systolic and diastolic BP for hypertension, serum glucose, and HbA1c for DM, triglyceride, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol for dyslipidemia. Hyperuricemia and higher SUA levels remained independent risk factors for hypertension both in men and in women after adjustments for age, sex, BMI, smoking and drinking habits, and baseline systolic and diastolic BP (Table  S3 , hypertension). Hyperuricemia and higher SUA levels also remained independent risk factors for dyslipidemia in men, but not in women after multiple adjustments for age, sex, BMI, smoking and drinking habits, baseline serum triglyceride, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol (Table S3 , dyslipidemia). In contrast, hyperuricemia and higher SUA levels were not an independent risk factor for DM in either sex after multiple adjustments with age, sex, BMI, smoking and drinking habits, and baseline serum glucose and HbA1c (Table  S3 , diabetes mellitus). These results document that asymptomatic hyperuricemia strongly predicts hypertension both in men and in women and dyslipidemia in men, but that the predictive effect of asymptomatic hyperuricemia on dyslipidemia in women or DM both in men and in women is either linked with other risk factors (eg, dyslipidemia) or is weak or absent (DM).
The importance of our study is that we evaluate subjects with asymptomatic hyperuricemia who lack cardiac and metabolic risk factors to determine if they are still at risk for cardiometabolic diseases. Few studies have used this approach, and most take all subjects with hyperuricemia, of which the majority already carry cardiometabolic comorbidities, such as hypertension, DM, dyslipidemia, CKD, and overweight/obesity. 26 We have looked at studies that investigated the effects of hyperuricemia in children, who often lack cardiometabolic comorbidities, with future development of cardiovascular events, but while hyperuricemia in childhood (including in blacks, Hispanics, and whites) does predict hypertension in adulthood, even in childhood children with hyperuricemia already have higher BP and BMI. 27, 28 Nevertheless, there are a few reports that hyperuricemia in healthy, normotensive Japanese individuals can predict the development of hypertension and weight gain. 29 There are also studies that show that hyperuricemia increases the risk for developing metabolic syndrome in both American 30 and Korean 31 adults, but again these studies did not eliminate underlying comorbidities, such as obesity prior to the analysis. Thus, the strength of our study is that we began by separating a subset of subjects who were normotensive, without DM, dyslipidemia, reduced eGFR, or overweight/obesity, and despite removing these comorbidities, hyperuricemia remained a risk factor for hypertension, dyslipidemia, CKD, and overweight/obesity in crude analyses. While this is likely true for all populations, this is really one of the first of these types of studies, and thus, the generalizability to other ethnic populations is a limitation.
Our finding that hyperuricemic subjects without hypertension, DM, dyslipidemia, CKD, and overweight/obesity have increased cardiometabolic risk factors is relevant to the general population. Hyperuricemia, defined as >7.0 mg/dL in men and ≥6.0 mg/dL in women, [17] [18] [19] [20] is extremely common, with the prevalence of >20% in both men and women in the United States. 20 Over half of these subjects have CKD and 50% have hypertension, as well as other morbidities. 26 Hyperuricemia is similarly elevated in the Japanese population. 32 Understanding whether subjects who are normotensive, without DM, dyslipidemia, CKD, or overweight/obesity still carry cardiometabolic risk if they are hyperuricemic is important and relative to the general population because hyperuricemia is so common. Indeed, in our study, the frequency of asymptomatic hyperuricemia in the absence of hypertension, DM, dyslipidemia, CKD, and overweight/obesity still amounted to 7% of our population, which reflects a significant number of people.
The potential mechanisms by which uric acid may cause hypertension or metabolic syndrome have been previously published, but includes the ability of uric acid to induce intracellular and mitochondrial oxidative stress, reduce endothelial nitric oxide bioavailability, and to stimulate the intracellular renin angiotensin system. 6 Hyperuricemia may also be a biomarker for activation of xanthine oxidase, which releases oxidants during the generation of uric acid. 33 Nevertheless, increasing SUA by inhibiting uricase raises in rats both systemic and glomerular BP and can accelerate CKD. 34, 35 Uric acid also induces lipogenesis in the liver and can block fatty acid oxidation. 36, 37 Hence, it remains plausible that SUA may have a causal role in mediating or modulating these conditions. This study has some limitations. First, this study was a retrospective, single-center study, which may introduce selection bias. There were 30 227 subjects (15 263 men) who underwent annual medical examination at the hospital in 2004. In this study, we enrolled 13 201 subjects who came at the hospital both in 2004 and in 2009; however, the background demographics was almost same. The prevalence of hyperuricemia between all the subjects in 2004 (7.3%) and this cohort study subjects (7.6%) after using the same exclusion criteria showed no significant differences (P=0.49), as well as in men (17.1% versus 17.8%; P=0.61) and in women (2.9% versus 3.4%; P=0.17), respectively (Table S4) . A positive aspect was that blood work was done in the same laboratory. We also excluded subjects with baseline hypertension, DM, dyslipidemia, and CKD, but this was based on the study design to assess the longitudinal metabolic and cardiorenal risks in asymptomatic hyperuricemia subjects without these conditions. Nevertheless, there remained significant differences at baseline between the normouricemic and hyperuricemic subjects, especially related to baseline eGFR, which was addressed by performing multivariable analysis. Our study was also limited in that it evaluated one ethnic group (Japanese), and similar studies need to be done with other populations to assess generalizability. Another limitation of this longitudinal study was the lack of time-to-event data, which precluded survival analysis. However, by excluding participants with known cardiorenal risk factors, we were able to evaluate the risk burden of hyperuricemia on cardiorenal diseases. Finally, the number of women with hyperuricemia was small, especially in the group with eGFR ≥75 mL/ min per 1.73 m 2 , in which only 81 women were hyperuricemic.
Perspectives
The importance of this study is that it shows that the presence of hyperuricemia in normotensive adults without overweight/ obesity carries a 2-to 3-fold risk for developing hypertension, CKD, and overweight/obesity within 5 years. Hyperuricemia is a valuable biomarker for predicting the development of cardiometabolic and renal diseases. Further prospective research is needed to evaluate whether strategies to reduce SUA over time can prevent these conditions.
